The
Asia-Pacific
scar treatment market size was valued at $3.6 billion in 2016, which
is forecasted to reach $7.8 billion by 2023, growing at a CAGR of 11.6% during
the 2017-2023. Among the various types of scar treatments, topical scar
treatment is expected to lead the scar treatment market in the region, followed
by surface, laser, injectable, and invasive surgical treatment. Increasing focus on personal well-being,
rising awareness about scar treatments and growing availability of non-invasive
and less expensive topical scar treatment products are expected to be the drive
the demand for topical scar treatment products.
Explore Report at: https://www.psmarketresearch.com/market-analysis/asia-pacific-scar-treatment-market
The
Asia-Pacific scar treatment market is expected to grow at a faster rate as
compared to other regions, due to increasing focus of general population on
personal well-being, rising disposable income and growing prevalence of skin
related problems such as burns, wounds and increasing number of cosmetic
procedures performed in the region. According to the WHO, approximately
1,000,000 people suffer from moderate or severe burns, every year. These burn
cases may lead to scar formation, leading to increased demand for scar
treatment products in the region. According to the International Society of
Aesthetic Plastic Surgery (ISAPS), the cosmetic surgeries performed in
countries such as South Korea and India, are increasing at a rapid rate. In
2015, total surgical procedures performed in South Korea was 445,144, and in
India, the number stood at 420,454.
The key players operating in the Asia-Pacific scar treatment market include Shanghai Fosun Pharmaceutical (Group) Company Limited, Beijing Toplaser Technology Company Limited, Sirnaomics, Inc., Essex Bio-Technology Limited, A. Menarini Asia-Pacific Holdings Pte. Ltd, Shiseido Company Limited, Concord Medisys Pvt. Ltd, Seoulin Bioscience Co. Ltd., Hanson Medical Inc., Otsuka Pharmaceutical Co., Ltd.
No comments:
Post a Comment